TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: The clinical benefits of BV have also been demonstrated, as monotherapy, in patients with relapsed or refractory (R/R) CD30-expressing PTCLs, including ALCL, PTCL-NOS, AITL, and CTCL [6, 13, 14].